Xilio Therapeutics, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Xilio (market cap ~$34.9M) received FDA clearance for IND application of XTX501, a bispecific PD-1/masked IL-2 therapy, with Phase 1 dosing expected in H2 2026 and initial data in H2 2027. The company is advancing two masked T cell engager programs (CLDN18.2 and PSMA+STEAP1) with IND submissions planned for H2 2027. Cash position is $136.0M as of June 30, 2026, with runway into Q1 2028; collaboration revenue from AbbVie and Gilead agreements increased to $18.7M in Q2 2026 vs. $8.1M in Q2 2025; net loss narrowed to $6.4M vs. $15.8M year-over-year.
Why this rating
IND clearance is meaningful clinical milestone for small biotech; cash runway ~15 months from filing date provides development visibility; collaboration revenue (~$18.7M quarterly) is substantial relative to $34.9M market cap but dependency on partners creates risk.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.